|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
children
infants
injection
newborns
upper arm
adults (in some cases)
|
|
gptkbp:ATCCode
|
gptkb:J07AN01
|
|
gptkbp:boosterRecommended
|
no
|
|
gptkbp:broadcastOn
|
single dose at birth or soon after
|
|
gptkbp:contains
|
gptkb:attenuated_Mycobacterium_bovis
|
|
gptkbp:contraindication
|
pregnancy
immunocompromised individuals
|
|
gptkbp:developedBy
|
gptkb:Camille_Guérin
gptkb:Albert_Calmette
|
|
gptkbp:duration
|
up to 10–20 years
|
|
gptkbp:effect
|
varies by region
high in preventing severe forms of TB in children
variable in adults
|
|
gptkbp:fullName
|
gptkb:Bacillus_Calmette–Guérin_vaccine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BCG vaccine
|
|
gptkbp:includedIn
|
gptkb:Expanded_Programme_on_Immunization_(EPI)
|
|
gptkbp:introducedIn
|
1921
|
|
gptkbp:namedAfter
|
gptkb:Camille_Guérin
gptkb:Albert_Calmette
|
|
gptkbp:notEffectiveAgainst
|
adult pulmonary TB (variable)
latent TB infection
|
|
gptkbp:notRoutinelyUsedIn
|
gptkb:Australia
gptkb:Canada
gptkb:Germany
gptkb:Italy
gptkb:Netherlands
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:prequalifiedBy
|
gptkb:World_Health_Organization
|
|
gptkbp:protectedBy
|
miliary tuberculosis
tuberculous meningitis in children
|
|
gptkbp:routeOfAdministration
|
intradermal
|
|
gptkbp:sideEffect
|
lymphadenitis
injection site ulceration
osteitis
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:type
|
live attenuated vaccine
|
|
gptkbp:usedFor
|
bladder cancer immunotherapy
prevention of tuberculosis
|
|
gptkbp:usedIn
|
countries with high TB incidence
many countries with high tuberculosis prevalence
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Albert_Calmette
gptkb:Bovine_tuberculosis
|
|
gptkbp:bfsLayer
|
5
|